Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Ibrutinib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ibrutinib as a study intervention. Browse Ibrutinib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
271
Shown on this page
12
Current sort
Recently updated
Therapy scope
Ibrutinib
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Ibrutinib. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 241–252 of 271 matching trials for Ibrutinib.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

NCT02415608
View directory record Official record
Conditions
Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
Interventions
Ibrutinib
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

NCT02351037
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Ibrutinib, Ibrutinib + LD-AraC, Ibrutinib+Azacitidine
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Withdrawn Phase 1 Interventional

Safety and Activity of SNX-5422 Plus Ibrutinib in CLL

NCT02914327
View directory record Official record
Conditions
Cancer
Interventions
SNX-5422 plus ibrutinib
Drug
Lead sponsor
Esanex Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Terminated Phase 1 Interventional

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02635074
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia
Interventions
Cytarabine, Ibrutinib, Idarubicin
Drug
Lead sponsor
Steven E. Coutre
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

NCT02841150
View directory record Official record
Conditions
Healthy
Interventions
IMBRUVICA (Treatment A), Ibrutinib (Treatment B)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Withdrawn Phase 1 Interventional

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

NCT02815059
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Ibrutinib, Dasatinib, Prednisone
Drug
Lead sponsor
University of Utah
Other
Eligibility
60 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Completed Phase 1 Interventional

Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02219737
View directory record Official record
Conditions
CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions
Carboplatin, Etoposide, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

NCT02200848
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Ibrutinib, Rituximab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 23, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

NCT01722487
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Chlorambucil
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
65 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Duarte, California • La Jolla, California • Santa Rosa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 23, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional

Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

NCT02455297
View directory record Official record
Conditions
Lymphoma, Mantle-Cell
Interventions
Copanlisib (BAY80-6946)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Baltimore, Maryland • Hackensack, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 23, 2026, 11:47 AM EDT
Withdrawn Phase 2 Interventional

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

NCT02662296
View directory record Official record
Conditions
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Idelalisib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 23, 2026, 11:47 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT02677948
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Pacritinib, Ibrutinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 23, 2026, 11:47 AM EDT

About this Ibrutinib clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Ibrutinib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ibrutinib.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Ibrutinib.